Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

A 49-year-old scientist successfully treated her breast cancer by using a virus she grew in the lab. Her self-treatment ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

Researchers found “no significant discrepancy in safety events” between trastuzumab biosimilars and the originator product.

Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2 ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

The government of India has mandated companies to reduce the prices of three anti-cancer drugs, Trastuzumab, Osimertinib, and ...

India's government has asked manufacturers to reduce prices of three anti-cancer drugs - Trastuzumab, Osimertinib and ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...